Exposure–Response Relationships for Efficacy and Safety of Risankizumab in Phase II and III Trials in Psoriasis Patients

Risankizumab has demonstrated efficacy in phase III trials in patients with moderate‐to‐severe plaque psoriasis. The exposure–response relationships for risankizumab efficacy (Psoriasis Area and Severity Index (PASI)75, PASI90, PASI100, and static Physician's Global Assessment (sPGA)0/1) at wee...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clin Pharmacol Ther
Hlavní autoři: Khatri, Amit, Suleiman, Ahmed A., Polepally, Akshanth R., Othman, Ahmed A.
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2019
Témata:
Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7006881/
https://ncbi.nlm.nih.gov/pubmed/31355921
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpt.1594
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky